Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pediatric Oncology Advances Could Prompt More FDA-Required Studies

May 16 2019

• By Mary Jo Laffler

IV solution in a child's patients hand - Image

Related Content

ASCO's Richard Schilsky On State-of-the-Art Oncology Trials

Dec 07 2017

Pediatric Cancer Studies: US FDA Promises Flexible Approach On Requirements

Feb 23 2018

Oncology Sponsors Getting A Jump On Pediatric Study Requirements, US FDA Says

Mar 26 2019

Roche’s Entrectinib Differentiates Itself From NSCLC Competitors With CNS Data

Sep 24 2018

FDA Nod For Loxo/Bayer Tissue Agnostic Drug Marks Paradigm Shift In Cancer

Nov 27 2018

What Late-Breakers To Look Out For At ASCO 2019

May 16 2019

Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy

Feb 18 2019

Roche’s EU Accelerated Assessment Bid For Tumor Agnostic Entrectinib Backfires

Mar 04 2019

Plenty Of Potential For Roche's Entrectinib Despite Lack Of ESMO Enthusiasm

Oct 24 2018

Genomics-Driven Trials Built To Be Fast And Flexible

Sep 21 2015

Related Companies

Roche Holding AG

Bayer AG

Eli Lilly and Company

Loxo Oncology at Lilly

Additional Topics

United States Pediatrics Clinical Trials Regulation Research & Development Cancer BioPharmaceutical

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window